Journal Article Summary
The article examines the occurrence of fractures in patients with primary biliary cholangitis (PBC) who were treated with seladelpar during a clinical trial. PBC is a chronic autoimmune disease that primarily affects women and can lead to liver damage and complications such as osteoporosis, which increases the risk of fractures. Understanding the relationship between seladelpar treatment and fracture risk is important, as patients with PBC may already be at a higher risk for bone health issues.
In the phase III RESPONSE trial, 193 patients with PBC were randomly assigned to receive either seladelpar or a placebo for 12 months. Among those treated with seladelpar, 4% experienced fractures, while none occurred in the placebo group. The study assessed the baseline bone health of participants and found that those receiving seladelpar had a higher prevalence of osteoporosis risk factors compared to the placebo group. Although some fractures were classified as likely or possibly osteoporotic, the overall fracture rate observed was consistent with what is expected in this patient population.
The study has limitations, including the small number of fractures reported and the lack of detailed information on the specific locations of the fractures. While the findings suggest a potential imbalance in fracture events between the treatment and placebo groups, no direct causal link between seladelpar and fractures was established. Patients with PBC should discuss their bone health and any concerns about fracture risk with their healthcare provider, particularly if they have a history of osteoporosis or related conditions, to ensure appropriate monitoring and management.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Vierling John M., Hirschfield Gideon M., Kustra Robert P., Liu Xiangyu, Proehl Sarah, Crittenden Daria B.. Fracture events in patients with primary biliary cholangitis during treatment with seladelpar in the phase III RESPONSE trial. Hepatology Communications 2025. DOI: 10.1097/HC9.0000000000000845. PMID: 41325090. PMCID: PMC12614673.
Featured Pill Pals Product
Cyclobenzaprine 5 mg Tablets --- Generic For Flexeril --- TruPharma
Cyclobenzaprine 5 mg Tablets — Generic For Flexeril — TruPharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
